HCKH - PI Maja Lindenmeyer - Hamburg Center for Kidney Health

Biobanking Study group

Maja Lindenmeyer

Maja Lindenmeyer

Mission Statement

“Facilitate translational renal research and provide a valuable source to accelerate the development of better patient diagnostics and therapies – only together we can make a difference”

— Maja Lindenmeyer, PhD

Team Members

Study nurse

Marigona Agushi

This email address is being protected from spambots. You need JavaScript enabled to view it.

Technician

Silvia Chilla

This email address is being protected from spambots. You need JavaScript enabled to view it.

Technician

Ilka Edenhofer

This email address is being protected from spambots. You need JavaScript enabled to view it.

CLINICIAN SCIENTIST

Sydney Gies, MD

This email address is being protected from spambots. You need JavaScript enabled to view it.

Study nurse

Inga Komisarenko

This email address is being protected from spambots. You need JavaScript enabled to view it.

Study nurse

Samaneh Liagos

This email address is being protected from spambots. You need JavaScript enabled to view it.

Clinician Scientist

Elisabeth Meister, MD

This email address is being protected from spambots. You need JavaScript enabled to view it.

Post Doc

Nikolay Zolotarev, PhD

This email address is being protected from spambots. You need JavaScript enabled to view it.

Research

Zoom

©Maja Lindenmeyer, created with BioRender

Our group represents the core facility of the “European Renal cDNA Bank-Kroener Fresenius Biopsy Bank” (ERCB-KFB), a multicenter study for gene expression analysis in different human renal diseases, and the “Hamburg and European Renal Omics Bank” (HERO), a collaborative project for conducting translational research in human renal diseases. Using state of the art omics and non-omics technologies, we aim to

support the renal scientific community by translational research
expand our knowledge of disease pathomechanisms
define molecular disease subgroups
identify biomarkers
find new ways treating human renal diseases.

Maja Lindenmeyer, PhD

LABORATORY HEAD/HEAD OF BIOBANK

III. Department of Medicine, University Medical Center Hamburg-Eppendorf (UKE)
Martinistr. 52
20246 Hamburg, Germany

This email address is being protected from spambots. You need JavaScript enabled to view it.

CV

Current Position

since 2024	Principal Investigator SFB 1192
since 2022	Principal Investigator / Co-Coordinator BMBF STOP-FSGS
since 2022	Principal Investigator BMBF UPTAKE
since 2021	Project Leader/ Study Coordinator of the Hamburg and European Renal Omics Biobank (HERO)
since 2018	Laboratory head, III. Department of Medicine, UKE, Prof. Dr. T. B. Huber
since 2018	Coordinator of the ERCB

University Training

1994 – 2000

Chemistry, Technical University Karlsruhe, University of Freiburg

Academic qualifications

2014 - 2020	Habilitation in Molecular Nephrology, University of Zurich (Switzerland)
2004	PhD, Department of Pharmaceutical Biology and Biotechnology, University of Freiburg
2000	Diploma in Chemistry, University of Freiburg

Previous professional career

2015 – 2018	Junior Group leader, Nephrology Center, IV. Department of Medicine, University Hospital of Munich (LMU)
2012 – 2018	Deputy-Coordinator of the European Renal cDNA Bank-Kroener Fresenius Biobank (ERCB)
2010 – 2014	Laboratory Head of the Nephrology Lab Zurich, University of Zurich (Switzerland)
2008 – 2010	Postdoctoral Fellow, Institute of Physiology and Division of Nephrology, University of Zurich (Switzerland), Prof. Dr. C. Cohen
2006 – 2007	Postdoctoral Fellow, Nephrology Center, IV. Deparment of Medicine, University Hospital of Munich (LMU), Prof Dr. C. Cohen
2004 – 2005	Postdoctoral Fellow, School of Biological Sciences, Queen Mary College, London (UK), Prof. Dr. M. Warren

Selected awards and honors

2010 - 2020	Habilitation Scholarship of the Holcim Foundation
2004 – 2005	Post-Doc fellowship of the German Academic Exchange Service (DAAD)
2001 – 2003	PhD fellowship of the “Landesgraduiertenförderung Baden-Württemberg”

Selected publications

1.	Molecular consequences of SARS-CoV-2 liver tropism. Wanner N, Andrieux G, Badia-i-Mompel P, Edler C, Pfefferle S, Lindenmeyer M, Schmidt-Lauber C, Czogalla J, Wong MN, Okabayashi Y, Braun F, Lütgehetmann M, Meister E, Lu S, Noriega MLM, Günther T, Grundhoff A, Fischer N, Bräuninger H, Lindner D, Westermann D, Haas F, Roedl K, Kluge S, Addo MM, Huber S, Lohse AW, Reiser J, Ondruschka B, Sperhake JP, Saez-Rodriguez J, Boerries M, Hayek SS, Aepfelbacher M, Scaturro P, Puelles VG, Huber TB. Nat Metab* 2022 Mar;4(3):310-319
2.	Pro-cachectic factors link experimental and human chronic kidney disease to skeletal muscle wasting. Solagna F, Tezze C, Lindenmeyer MT, Lu S, Wu G, Liu S, Zhao Y, Mitchell R, Meyer C, Omairi S, KilicT, Paolini A, Ritvos O, Pasternack A, Matsakas A, Kylies D, Wiesch JS zur, Turner J-E, Wanner N, Nair V, Eichinger F, Menon R, Martin I V., Klinkhammer BM, Hoxha E, Cohen CD, Tharaux P-L, Boor P, Ostendorf T, Kretzler M, Sandri M, Kretz O, Puelles VG, Patel K, Huber TB, J Clin Invest.* 2021 Jun 1;131(11).
3.	Endothelial-Specific Deletion of CD146 Protects Against Experimental Glomerulonephritis in Mice. Abed A, Leroyer AS, Kavvadas P, Authier F, Bachelier R, Foucault-Bertaud A, Bardin N, Cohen CD, Lindenmeyer MT, Genest M, Joshkon A, Jourde-Chiche N, Burtey S, Blot-Chabaud M, Dignat-George F, Chadjichristos CE. Hypertension.* 2021 Apr;77(4):1260-1272
4.	SARS-CoV-2 renal tropism associates with acute kidney injury. Braun F, Lütgehetmann M, Pfefferle S, Wong MN, Carsten A, Lindenmeyer MT, Nörz D, Heinrich F, Meißner K, Wichmann D, Kluge S, Gross O, Pueschel K, Schröder AS, Edler C, Aepfelbacher M, Puelles VG, Huber TB. Lancet. 2020 Aug;396(10251):597–8.
5.	ADAM10-Mediated Ectodomain Shedding Is an Essential Driver of Podocyte Damage. Sachs M, Wetzel S, Reichelt J, Sachs W, Schebsdat L, Zielinski S, Seipold L, Heintz L, Müller SA, Kretz O, Lindenmeyer M, Wiech T, Huber TB, Lüllmann-Rauch R, Lichtenthaler SF, Saftig P, Meyer-Schwesinger C. J Am Soc Nephrol. 2021 Jun 1;32(6):1389-1408
6.	Dysregulated mesenchymal PDGFR-β drives kidney fibrosis Buhl EM, Djudjaj S, Klinkhammer BM, Ermert K, Puelles VG, Lindenmeyer MT, Cohen CD, He C, Borkham-Kamphorst E, Weiskirchen R, Denecke B, Trairatphisan P, Saez-Rodriguez J, Huber TB, Olson LE, Floege J, Boor P. EMBO Mol Med. 2020 Mar 6;12(3):e11021
7.	Multiorgan and Renal Tropism of SARS-CoV-2. Puelles VG, Lütgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, Chilla S, Heinemann A, Wanner N, Liu S, Braun F, Lu S, Pfefferle S, Schröder AS, Edler C, Gross O, Glatzel M, Wichmann D, Wiech T, Kluge S, Pueschel K, Aepfelbacher M, Huber TB. N Engl J Med. 2020 Aug 6;383(6):590–2.
8.	Tubular NOX4 expression decreases in chronic kidney disease but does not modify fibrosis evolution. Rajaram RD, Dissard R, Faivre A, Ino F, Delitsikou V, Jaquet V, Cagarelli T, Lindenmeyer M, Jansen-Duerr P, Cohen C, Moll S, de Seigneux S. Redox Biol. 2019 Sep;26:101234
9.	Metabolic pathways and immunometabolism in rare kidney diseases. Grayson PC, Eddy S, Taroni JN, Lightfoot YL, Mariani L, Parikh H, Lindenmeyer MT, Ju W, Greene CS, Godfrey B, Cohen CD, Krischer J, Kretzler M, Merkel PA; Vasculitis Clinical Research Consortium, the European Renal cDNA Bank cohort, and the Nephrotic Syndrome Study Network. Ann Rheum Dis. 2018 Aug;77(8):1226-1233.
10.	Transcriptome-based network analysis reveals renal cell type-specific dysregulation of hypoxia-associated transcripts. Shved N, Warsow G, Eichinger F, Hoogewijs D, Brandt S, Wild P, Kretzler M, Cohen CD, Lindenmeyer MT. Sci Rep. 2017 Aug 17;7(1):8576. *contributed equally